Roman Fabbricatore

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo.

Device programming encounters near the end of life occurred in nearly half of patients with ICDs, offering a potential opportunity for goals-of-care discussions.

Updated results from the phase 3 CheckMate-8HW trial continue to show fewer severe (grade 3/4) side effects with nivolumab/ipilimumab compared to chemotherapy.

Analysis of two trials indicates psilocybin-assisted psychotherapy may benefit the mental health of patients with cancer.

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with infrequent surgical complications.

The phase 3 KEYNOTE-826 trial met its dual primary end points of overall and progression-free survival in patients with cervical cancer.

Treatment with venetoclax plus hypomethylating agents yielded improved response rates among adult patients with myelodysplastic syndrome.

According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer survival; however, rates have improved in the last 5 years regardless.

While pregnancy-associated cancer risks increased with age, breast cancer during pregnancy tended to not impact obstetric risk.

The addition of lurbinectedin to atezolizumab improved OS and PFS in patients with extensive-stage small cell lung cancer.

A gene assay was predictive of response to extended letrozole therapy, identifying a subset of patients with low-risk breast cancer with improved outcomes.

New guidelines for basal cell and squamous cell carcinoma provide detailed criteria for diagnosing, staging, IGRST, and follow-up, among others.

A learning approach integrating time series and static data may improve understanding of breast cancer outcomes.

Genetic testing offers potential benefits after a cancer diagnosis by potentially reducing the risk for cancer in families with hereditary cancer syndromes and managing treatment.

Based on in vitro studies, this tetravalent bispecific antibody may show binding affinity to PD1 and VEGF.

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.

Findings from this study also demonstrate statistically meaningful improvements in breast cancer–specific quality of life and endocrine symptoms with acupuncture.

The fast track status from the FDA is supported by findings from a phase 1 trial in glioblastoma, which demonstrated the overall survival benefit from DOC1021.

Follow-up with cholesterol control and audiological assessments is suggested for cisplatin-treated patients with cancer.

This recommendation is an update to the 2020 ASCO guideline on optimal adjuvant chemotherapy and targeted therapy for the treatment of breast cancer.